Core Points - Weigao Group has signed a non-binding letter of intent to acquire 100% equity of Weigao Puri through Weigao Blood Purification [1] - Weigao Blood Purification specializes in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] - Weigao Puri focuses on the development and production of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [1] Business Synergy - The potential transaction is expected to create business synergies between Weigao Puri and Weigao Blood Purification, further expanding the overall business landscape of the group [2]

Group 1 - The core point of the news is that Weigao Co., Ltd. has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. by issuing consideration shares to its shareholders [1] - The potential transaction involves Weigao Blood Purification, which is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group Co., Ltd., with Weigao Co., Ltd. holding a 23.53% stake in Weigao Blood Purification [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of Weigao Co., Ltd., with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by Weigao Co., Ltd., Weihai Shengxi, and Weihai Ruiming, respectively [2] Group 3 - Related events include the potential injection of Weigao Blood Purification into Weigao Purui and the resignation of Yan Xia as Vice Chairman and Non-Executive Director of Weigao Co., Ltd. [3]

威高血净是一家在中国设立的公司，其A股在上海证券交易所上市（证券代码：603014.SH）。该公司 主要从事血液净化医用制品的研发、生产和销售，主要产品包括血液透析器、血液透析管路、血液透析 机以及腹膜透析液，分别围绕血液透析和腹膜透析领域，辅以透析配套产品的销售。截至本公告日期， 威高血净由公司控股股东威高集团有限公司控股。公司亦直接持有威高血净23.53%的股份。 威高普瑞聚焦预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售，致力于为全球生物 制药企业提供一站式药品递送整体解决方案。截至本公告日期，威高普瑞为公司的非全资附属公司，由 公司、威海盛熙和威海瑞明分别持有94.0706%、4.0215%及1.9078%的股权。 格隆汇10月17日丨威高股份(01066.HK)宣布，于2025年10月17日，公司、威海盛熙企业管理谘询中心、 威海瑞明企业管理谘询合夥企业，连同公司和威海盛熙合称「威高普瑞股东」)及山东威高血液净化制 品股份有限公司签订了一份不具法律约束力的意向书，据此威高血净向各威高普瑞股东发行对价股份以 收购山东威高普瑞医药包装有限公司100%的股权(「潜在交易」)。意向书仅为交易各 ...

格隆汇10月17日丨威高股份(01066.HK)宣布，于2025年10月17日，公司、威海盛熙企业管理谘询中心、 威海瑞明企业管理谘询合夥企业，连同公司和威海盛熙合称「威高普瑞股东」)及山东威高血液净化制 品股份有限公司签订了一份不具法律约束力的意向书，据此威高血净向各威高普瑞股东发行对价股份以 收购山东威高普瑞医药包装有限公司100%的股权(「潜在交易」)。意向书仅为交易各方就潜在交易达成 的初步意向，潜在交易的交易条款须由交易各方另行协商并签署正式交易文件确定。于本公告之日，各 方并未就潜在交易订立具法律约束力的正式协议。 威高普瑞聚焦预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售，致力于为全球生物 制药企业提供一站式药品递送整体解决方案。截至本公告日期，威高普瑞为公司的非全资附属公司，由 公司、威海盛熙和威海瑞明分别持有94.0706%、4.0215%及1.9078%的股权。 威高血净是一家在中国设立的公司，其A股在上海证券交易所上市（证券代码：603014.SH）。该公司 主要从事血液净化医用制品的研发、生产和销售，主要产品包括血液透析器、血液透析管路、血液透析 机以及腹膜透析液，分别围 ...